Please assess the completion status of the following clinical trial:

Trial Title: Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Recipient of a first (primary) live or deceased (after brain or cardiac death) donor liver transplant~* Willing and able to provide written informed consent~* Male or Female, age 18-70 years old~* Medical MELD score ≤30 at time of transplant (calculated based on serum bilirubin, creatinine and INR, i.e. not taking exception points into account)~* Quantifiable HCV RNA at time of listing or transplant evaluation~* HCV genotype 1a or 1b infection~* Female patients must have a negative pregnancy test at enrolment~Exclusion Criteria:~* Liver re-transplantation~* Recipients of multiple solid organ transplants~* Estimated GFR \<30ml/min at time of transplant~* Participants transplanted for fulminant hepatic failure~* Participants co-infected with HBV or HIV~* Previous treatment with a Sofosbuvir or Ledipasvir containing regimen~* Participation in an interventional clinical trial within 1 month prior to enrolment~* Known allergies or hypersensitivity to Sofosbuvir or Ledipasvir~* Pregnancy and/or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- SOF and LDV (Type: EXPERIMENTAL): Single arm: All participants will be started on Sofosbuvir (SOF) 400 mg and Ledipasvir (LDV) 90 mg as a fixed dose combination (FDC) tablet p.o. once daily with or without food starting at the time of liver transplantation (OLT), i.e. first doses given immediately prior to OLT, and continuing for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).